3-ethyl-2-methoxy-6-methyl-5-(1,3,4-oxadiazol-2-yl)pyridine | 867006-98-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-ethyl-2-methoxy-6-methyl-5-(1,3,4-oxadiazol-2-yl)pyridine
• 英文别名: 3-Ethyl-2-methoxy-6-methyl-5-[1,3,4]oxadiazol-2-yl-pyridine；2-(5-ethyl-6-methoxy-2-methylpyridin-3-yl)-1,3,4-oxadiazole
• CAS: 867006-98-2
• 化学式: C₁₁H₁₃N₃O₂
• 分子量: 219.243
• InChiKey: SQQMYTFKGNRNNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  61
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-ethyl-2-methoxy-6-methyl-5-(1,3,4-oxadiazol-2-yl)pyridine 在 三甲基氯硅烷 、 sodium iodide 、 水 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以21%的产率得到3-ethyl-6-methyl-5-(1,3,4-oxadiazol-2-yl)-1H-pyridin-2-one
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  [FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)

  摘要：

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。

  公开号：

  WO2005097750A1
• 作为产物：
  描述：

  5-ethyl-6-methoxy-2-methylnicotinic acid N'-formylhydrazide 在 对甲苯磺酰氯 作用下， 以 四氢呋喃 为溶剂， 145.0 ℃ 、600.01 kPa 条件下， 反应 0.05h， 以8%的产率得到3-ethyl-2-methoxy-6-methyl-5-(1,3,4-oxadiazol-2-yl)pyridine
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  [FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)

  摘要：

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。

  公开号：

  WO2005097750A1

文献信息

• SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：Weintraub M. Philip

  公开号：US20070032489A1

  公开（公告）日：2007-02-08

  The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R 1 , R 2 , R 3 and R 4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明涉及一系列公式I的2,3,5-取代吡啶酮衍生物，其中R，R1，R2，R3和R4如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是聚腺苷酸二磷酸核糖聚合酶（PARP）的抑制剂，因此在治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病有关的疾病方面，具有药物学上的用途。
• Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US08173682B2

  公开（公告）日：2012-05-08

  The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明涉及一系列式I的2,3,5-取代吡啶酮衍生物，其中R、R1、R2、R3和R4如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是聚腺苷酸二磷酸核糖聚合酶（PARP）的抑制剂，因此在医药领域中具有广泛的应用，特别是在治疗和/或预防多种疾病，包括与中枢神经系统和心血管疾病相关的疾病方面。
• BIOCOMPATIBLE POLYMER COMPOSITIONS FOR DUAL OR MULTISTAGED CURING
  申请人：Commonwealth Scientific and Industrial Research Organization (CSIRO)

  公开号：EP1720925A1

  公开（公告）日：2006-11-15
• US8173682B2
  申请人：——

  公开号：US8173682B2

  公开（公告）日：2012-05-08
• [EN] BIOCOMPATIBLE POLYMER COMPOSITIONS FOR DUAL OR MULTISTAGED CURING<br/>[FR] COMPOSITIONS POLYMERIQUES BIOCOMPATIBLES POUR LE DURCISSEMENT DOUBLE OU A PLUSIEURS ETAPES
  申请人：COMMW SCIENT IND RES ORG

  公开号：WO2005085312A1

  公开（公告）日：2005-09-15

  The present invention provides a biocompatible polymer composition for use in biomedical applications comprising a base molecule, a linker molecule and at least one initiator compound, said base molecule having at least two differing functionalities, and said linker molecule having a functionality reactive with at least one functionality of said base molecule, the first of said at least two functionalities of said base molecule enabling a first curing stage of said polymer composition by reaction with said linker molecule, and the second and any further functionality of said base molecule enabling second and further curing stages of said polymer composition, said first, second and any further curing stages being capable of activation simultaneously or independently of each other as required. The invention further provides uses of the polymer compositions of the invention in biomedical applications such as tissue engineering, dry delivery, as a bioadhesive in wound healing, as bone substitutes or scaffolds, as cements in dental and periodontal applications and as anti-adhesives or protective barriers.